world
Insmed Halts Development of TPX-201 for Hidradenitis Suppurativa After Phase 2 Trial Failure
Insmed Incorporated announced the discontinuation of its topical drug TPX-201 for hidradenitis suppurativa following negative results from a Phase 2 clinical trial. The trial did not meet its primary endpoint of achieving Hidradenitis Suppurativa Clinical Response at Week 12. The company plans to focus resources on other pipeline programs.
Apr 7, 4:45 PM·2m read1 source
RE
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
Insmed Incorporated, a biopharmaceutical company based in Bridgewater, New Jersey, has discontinued the development of TPX-201, a topical formulation of a JAK1 inhibitor, intended for the treatment of hidradenitis suppurativa. Hidradenitis suppurativa is a chronic inflammatory skin condition affecting approximately 1% of the global population, characterized by painful nodules, abscesses, and scarring in areas such as the armpits and groin.
The decision follows the completion of the Phase 2 INSPIRE trial, which evaluated the drug's efficacy and safety.
The INSPIRE trial was a randomized, double-blind, placebo-controlled study involving 151 adult patients with moderate to severe hidradenitis suppurativa. Participants received either TPX-201 or a vehicle control applied topically twice daily for 12 weeks.
According to Insmed, the trial did not achieve its primary endpoint, defined as the proportion of patients attaining a Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 12 compared to placebo.
Insmed reported that while TPX-201 demonstrated a favorable safety profile with no serious treatment-related adverse events, the efficacy data fell short of expectations.
The company stated that the results did not support further advancement of the program. Insmed's Chief Executive Officer, William Forbes, commented on the outcome in a prepared statement.
“We are disappointed by the topline results from the INSPIRE study, which did not meet the primary endpoint. We remain committed to advancing innovative therapies for patients with serious unmet medical needs.”
